66th ASH Annual Meeting: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies

Symposia: Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, Adult, Fundamental Science, MDS, Lymphoid Leukemias, ALL, Translational Research, Assays, CHIP, Clinical Research, Bioinformatics, Genomics, Chronic Myeloid Malignancies, Hematopoiesis, Diversity, Equity, and Inclusion (DEI), Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, Technology and Procedures, Molecular biology, Study Population, Human, Natural Killer (NK) Cell Therapies, Pathogenesis, Omics technologies

Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

Moderators:

Ing Soo Tiong, FRACP, FRCPA, MPhil, ARRAY(0xe8d65b0) and Brent Ferrell Jr., MD, Vanderbilt University School of Medicine

Disclosures:

Tiong: Novartis: Speakers Bureau; Jazz: Honoraria; Pfizer: Speakers Bureau. Ferrell: Novartis: Research Funding.

4:00 PM

325

Genetic and Functional Characterization of NUP98-Rearranged Leukemia

Masayuki Umeda, MD, PhD¹, Nicole L Michmerhuizen, PhD², Ryan Hiltenbrand²^*, Juan M Barajas, PhD², Bright Arthur²^*, Michael P Walsh, PhD²^*, Guangchun Song²^*, Jing Ma, PhD²^*, Tamara Westover², Petri Pölönen, PhD², Cristina Mecucci, MD, PhD³, Danika Di Giacomo, PhD⁴^*, Franco Locatelli, MD⁵, Riccardo Masetti, MD, PhD⁶^*, Salvatore Bertuccio, PhD⁷^*, Martina Pigazzi, PhD⁸^*, Ilaria Iacobucci, PhD⁹, Charles G. Mullighan, MBBS, MSc, MD² and Jeffery M Klco, MD, PhD²

¹Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN
²Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
³Hematology, CREO, Centro Ricerche Emato-Oncologiche, University of Perugia, Perugia, Italy
⁴University of Perugia, Perugia, Italy
⁵IRCCS, Ospedale Pediatrico Bambino Gesù Rome, Catholic University of the Sacred Heart, Rome, Italy
⁶Pediatric Hematology-Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
⁷IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
⁸Department of Women's and Children's Health, Onco-hematology lab and clinic, University of Padova, Padova, Italy
⁹St. Jude Children's Research Hospital, Memphis, TN

4:15 PM

326

KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

Leah Kravets, MS¹, Mirca S. Saurty-Seerunghen, PhD²^*, Divij Verma, PhD¹, Ariel Fromowitz, MD³, Srabani Sahu, MS¹^*, Bradley Rockwell, MD⁴, Olivia Sakaguchi²^*, Swathi Narayanagari, MS⁵^*, Shanisha Gordon Mitchell¹^*, Milagros Carbajal¹^*, Srinivas Aluri, PhD¹, Jingli Wang, PhD⁵^*, Lindsay Lafave, PhD⁵^*, Marina Konopleva, MD⁶, Anna S. Nam, MD² and Amit Verma, MD¹

¹Blood Cancer Institute, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY
²Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Blood Cancer Institute, Department of Oncology, Albert Einstein College of Medicine, New York, NY
⁵Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY
⁶Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY

4:30 PM

327

Phip Is a Potent Leukemia Oncogene Identified in Acute Myeloid Leukemia (AML) Patients of African Ancestry

Bailee N. Kain, PhD¹, Sidharth Sen, PhD²^*, Deedra Nicolet, MS³^*, Sierra N. Bennett, BS¹^*, David Bernardicius, BS¹^*, Yueh-Chiang Hu, PhD^4,5^*, Christopher Walker, PhD³^*, Ann-Kathrin Eisfeld, MD^3,6,7, Nathan Salomonis, PhD^2,8^* and H. Leighton Grimes, PhD¹

¹Division of Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH
²Division of Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH
³The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁴Transgenic Animal and Genome Editing Core, Cincinnati Children's Hospital, Cincinnati, OH
⁵Department of Pediatrics, University of Cincinnati, Cincinnati, OH
⁶The Ohio State University, Columbus, OH
⁷Alliance Statistics and Data Management Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁸Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

4:45 PM

328

Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia

Yu Liu^1,2^*, Wenbing Liu¹^*, Yihan Mei¹^*, Qing Rao³^*, Runxia Gu, MD³^*, Min Wang¹^*, Jianxiang Wang, MD¹ and Shaowei Qiu, MD¹^*

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
²Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China

5:00 PM

329

Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity

Hanna Duàn, MSc^1,2,3^*, Emmi Jokinen^1,4,5^*, Hanna Lähteenmäki, MSc^1,2,3^*, Jay Klievink, M.Sc^1,3,5^*, Jonas Bouhlal, MSc, BSc^1,3,6^*, Essi Laajala, PhD^1,2,3^*, Jason Theodoropoulos, MSc^1,3,6^*, Heikki Kuusanmäki, PhD^7,8,9^*, Tanja Ruokoranta, MSc⁹^*, Pauliina Rumm^1,3^*, Dean Anthony Lee, MD, PhD¹⁰, Esa Pitkänen, PhD^6,9,11^*, Tomi P Mäkelä, MD, PhD^6,12^*, Kimmo Porkka, MD, PhD^1,4,13,14, Oscar E. Brück, MD, PhD¹⁵^*, Olli Dufva, MD, PhD^1,2,3^* and Satu Mustjoki, MD, PhD^1,4,14

¹Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
²iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland
³Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
⁴Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
⁵iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
⁶ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland
⁷Biotech Research & Innovation Centre (BRIC) and Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark
⁸Foundation for the Finnish Cancer Institute, Helsinki, Finland
⁹Institute for molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
¹⁰Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH
¹¹Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland
¹²HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
¹³Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
¹⁴ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
¹⁵Hematoscope Lab, Comprehensive Cancer Center & Center of Diagnostics, Helsinki University Hospital & University of Helsinki, Helsinki, Finland

5:15 PM

330

TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Li Li, MD, PhD¹^*, Muharrem Muftuoglu, MD¹, Edward Ayoub, PhD¹^*, Aram Bidikian, MD²^*, Prashant Menon, Ph.D³^*, Jiangxing Lv¹^*, Mahesh Basyal, BSc¹^*, Andrea Bedoy¹^*, Anudishi Tyagi, PhD²^*, Amanda Eckstrom, B.S.²^*, Venkata Lokesh Battula, PhD⁴, Navin Varadarajan, PhD³^*, Ghayas C. Issa, MD² and Michael Andreeff, MD, PhD¹

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³University of Houston, Houston, TX
⁴Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

618A.O1.6 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies